Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
Posted: 17 September 2021 | Eurofins Discovery | No comments yet
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
Eurofins Beacon Discovery is an industry leader in GPCR drug discovery offering an integrated approach for challenging GPCR targets. The Beacon Team has identified in excess of 30 pre-clinical candidates of which more than 20 programs have moved successfully into clinical development. Beacon Discovery employs an integrated workflow that will fully support your discovery program. Learn how you can take advantage of Eurofins Beacon Discovery’s capabilities now!
Related content from this organisation
- Human iPSC-derived cardiomyocytes for cardiac proarrhythmic risk assessment
- Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
- Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
- Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes
- Hit discovery for GPCRs: HTS or virtual screens?
Related topics
Assays, Disease research, GPCRs, High Throughput Screening (HTS), Hit-to-Lead, Immunology, In Vivo, Informatics, Screening, Targets
Related organisations
Eurofins Discovery
